AstraZeneca opens $1 billion R&D center in Boston's Kendall Square

AstraZeneca has opened a new $1 billion, 18-story research and development center in Kendall Square, Cambridge, Massachusetts. The 570,000-square-foot facility will house up to 3,000 employees in the coming years and utilizes advanced robotics and agentic AI to accelerate drug discovery. Alongside this opening, CEO Pascal Soriot highlighted AstraZeneca's recent $2 billion investment in Summit Therapeutics to develop next-generation cancer combinations using the bispecific antibody ivonescimab.

The new Kendall Square R&D center

• ▪Scientists at the new Kendall Square facility will develop treatments for oncology, cell therapy, chronic diseases like COPD and obesity, and rare diseases.
• ▪AstraZeneca opened a new 18-story, 570,000-square-foot global strategic research and development center at 290 Binney Street in Kendall Square, Cambridge, Massachusetts, on October 5, 2026.
• ▪The new AstraZeneca research and development center in Kendall Square represents a $1 billion investment and features ten floors of interconnecting laboratories.
• ▪The Kendall Square facility will house 1,100 AstraZeneca employees by the end of 2026, with plans to expand the company's total Massachusetts workforce by over 50% to 3,000 employees in the coming years.

Integration of robotics and artificial intelligence

• ▪AstraZeneca allocated approximately 20% of its $1 billion investment in the Kendall Square facility toward robotics and artificial intelligence technologies.
• ▪The Kendall Square facility includes a "lab of the future" designed to run continuous biologics research using artificial intelligence, automated machines, and pipetting robots.

Governor Healey's perspective

• ▪Massachusetts Governor Maura Healey urged public-private collaboration to ensure the state's life sciences ecosystem remains competitive against other states and countries.
• ▪Massachusetts Governor Maura Healey characterized AstraZeneca's $1 billion investment as a major vote of confidence in the state's life sciences talent and ecosystem.

AstraZeneca's local presence

• ▪AstraZeneca's existing footprint in Massachusetts includes a genomic medicine site at 100 Binney Street in Cambridge and offices in Boston's Seaport district.
• ▪Massachusetts hospitals participated in more than 25% of AstraZeneca's 200-plus clinical trials in 2025.

Collaboration with Summit Therapeutics

• ▪AstraZeneca CEO Pascal Soriot plans to combine Summit Therapeutics' lead drug with AstraZeneca's portfolio of antibody-drug conjugates to target specific tumor types.
• ▪AstraZeneca announced a $2 billion equity investment (approximate 12% stake) and clinical collaboration with Summit Therapeutics, which retains full commercial rights to its lead drug, to test potential cancer drug combinations.

Mechanism and efficacy of ivonescimab

• ▪Summit Therapeutics' lead drug, ivonescimab, is a first-in-class bispecific antibody that attacks cancer by simultaneously blocking PD-1 and VEGF pathways.
• ▪Head-to-head clinical trials showed that Summit Therapeutics' ivonescimab outperformed Merck's immunotherapy drug Keytruda in patients with advanced non-small cell lung cancer.

Competition from China

• ▪China has exponentially expanded its scientific research capacity in recent years, emerging as a major competitor to the Massachusetts biotechnology sector.
• ▪AstraZeneca executive vice president Sharon Barr stated that the company views China's growing scientific research capacity as both a collaboration opportunity and competition.

Debatable claims

• ▪The concentration of biotechnology R&D in elite hubs like Kendall Square does more harm than good
• ▪AI and robotics are reliable enough to replace human researchers in primary drug discovery